Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by ELKON, K. B.
Right arrow Articles by ASHANY, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ELKON, K. B.
Right arrow Articles by ASHANY, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 British Society for Rheumatology

research-article

THE SCID MOUSE AS A VEHICLE TO STUDY AUTOIMMUNITY

K. B. ELKON and D. ASHANY

Hospital for Special Surgery 535 E. 70th street, Cornell University Medical Center, New York, NY 10021, USA

Correspondence to: Correspondence to K. B. Elkon

Peripheral blood mononuclear cells (PBMC) injected into severe combined immune deficiency (SCID) mice continue to secrete human immunoglobulin and respond to immunization with recall antigens. PBMC from patients with autoimmune diseases produce autoantibodies of the same specificities but at lower levels compared to the donor. SCID recipients of patients' PBMC fail to develop clinical disease although some histological lesions suggestive of autoimmunity have been reported. Transfer of autoimmunity from rodents to SCID mice has been successful in some instances. Despite obstacles related to limited survival and varying degrees of graft vs host disease (GVHD), SCID mice should prove to be a useful vehicle to explore autoantibody regulation.

KEY WORDS: SCID mouse, Graft vs host disease, Autoantibodies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
G A W Bruyn, G Tate, F Caeiro, J Maldonado-Cocco, R Westhovens, H Tannenbaum, M Bell, O Forre, O Bjorneboe, P P Tak, et al.
Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study
Ann Rheum Dis, August 1, 2008; 67(8): 1090 - 1095.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
F. Breedveld, S. Agarwal, M. Yin, S. Ren, N. F. Li, T. M. Shaw, and B. E. Davies
Rituximab Pharmacokinetics in Patients With Rheumatoid Arthritis: B-Cell Levels Do Not Correlate With Clinical Response
J. Clin. Pharmacol., September 1, 2007; 47(9): 1119 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
R. H. Carter
B Cells in Health and Disease
Mayo Clin. Proc., March 1, 2006; 81(3): 377 - 384.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.